In the S1801 trial, patients with stage IIIB-IV operable melanoma were treated with three doses of pembrolizumab leading up to surgery, then an additional 15 doses following surgery, achieved better EFS than those receiving upfront surgery followed by 18 cycles of the same anti PD-1 drug [89]. The gene discussed is PDCD1; the disease is melanoma.